title: [Brain distribution of idebenone (CV-2619) and its effect on local cerebral glucose utilization in rats].
abstract: To investigate the possible action-sites of a cerebral metabolism activator, idebenone (CV-2619), its distribution in the brain and effect on local cerebral glucose utilization (LCGU) were studied both in normal rats (WKY) and in stroke-prone spontaneously hypertensive rats (SHRSP) with cerebrovascular lesions. At 5 min after intravenous administration of [14C] CV-2619 (10 mg/kg), the distribution ratio in the brain was 0.45-0.56% of the dosage. Autoradiographic study showed that 14C levels were higher in the white matter than in the grey matter. When [14C] CV-2619 was administered orally (100 mg/kg) and intraperitoneally (30 mg/kg), 14C levels in eleven brain regions (15 min after administration) were 0.22-0.39 microgram/g (CV-2619 equivalent) and 1.11-1.30 micrograms/g, respectively, in WKY and 0.17-0.28 microgram/g and 1.66-1.87 microgram/g, respectively, in SHRSP. Total 14C levels were not markedly different among the brain regions of the rats. The analysis of unchanged CV-2619 and its metabolites revealed that unchanged CV-2619 in the cerebral cortex, thalamus and cerebellum was relatively higher than that in the other brain regions. Studies on LCGU demonstrated that CV-2619 (30 mg/kg/day, i.p., for 3 days) improved the decrement of LCGU in the temporal cortex, thalamus dorsomedial nucleus, subthalamic nucleus, mamillary body, hippocampus dentate gyrus, caudate-putamen, inferior colliculus and cerebellar nucleus of SHRSP with stroke. Based on these results, the possible action-sites of CV-2619 for its main pharmacological effects were discussed.
mesh_terms: D000284:Administration, Oral; D000818:Animals; D016227:Benzoquinones; D001921:Brain / Q000378:metabolism*; D002561:Cerebrovascular Disorders / Q000188:drug therapy* / Q000378:metabolism; D005947:Glucose / Q000378:metabolism*; D007275:Injections, Intravenous; D008297:Male; D011809:Quinones / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D011918:Rats, Inbred SHR; D011919:Rats, Inbred Strains; D011921:Rats, Inbred WKY; D014451:Ubiquinone / Q000031:analogs & derivatives
chemical_list: D016227:Benzoquinones; D011809:Quinones; D014451:Ubiquinone; C036619:idebenone; D005947:Glucose